Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial [PDF]
Vaccines, 2023 (1) Background: This study aimed to compare the immunogenicity of the mix-and-match CoronaVac/BNT162b2 vaccination to the homologous CoronaVac/CoronaVac regimen.
Imen Zamali +2 more
exaly +6 more sources
Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study [PDF]
Vaccines, 2023 Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has outpaced vaccine availability and delivery from vaccine manufacturers, and thus, a scarcity of vaccines happened to many countries around the world.
Siriporn Okonogi +2 more
exaly +6 more sources
Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster [PDF]
Antibodies, 2022 Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose.
Tarchoon Aw, Michael Lau, Jianxin Huo
exaly +4 more sources
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines [PDF]
Human Vaccines & Immunotherapeutics, 2022 Mass vaccination with a safe and effective vaccine may be the best way to control the COVID-19 pandemic. Heterologous prime-boost vaccination with the CoronaVac and AZD1222 vaccines may increase the immunogenicity elicited by either vaccine alone.
Guy Cohen +11 more
doaj +2 more sources
A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting [PDF]
Scientific ReportsThis 22-month cohort study investigated the durability and dynamics of humoral immune responses in 327 Malaysians vaccinated with either CoronaVac or BNT162b2 in early 2021, monitored up to 52 weeks following a BNT162b2 booster. Using the ImmuSAFE™ COVID
Aini Syahida Mat Yassim +11 more
doaj +2 more sources
Frontiers in Immunology, 2022 BackgroundEffective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the ...
Rafaella F. Q. Grenfell +37 more
doaj +1 more source
Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
Human Vaccines & Immunotherapeutics, 2023 This open-labeled non-inferiority trial evaluated immunogenicity and reactogenicity of heterologous and homologous COVID-19 vaccination schedules in pregnant Thai women.
Chenchit Chayachinda +16 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2021 The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected ...
Ahmet Soysal +8 more
doaj +1 more source
Clinical and Experimental Hypertension, 2022 Objective This study aimed to observe the association between the presence of hypertension with Covid-19 vaccine effectiveness among healthcare workers who received CoronaVac vaccination.
Achmad Rifai +9 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2022 Protective neutralizing antibody titers reduce in time after COVID-19 vaccinations, as in individuals who have had COVID-19. This study aimed to evaluate the safety and immunogenicity of CoronaVac and TURKOVAC vaccines used as a booster dose after ...
Ahmet Omma +20 more
doaj +1 more source